Category: piperidines

On February 1, 2019, Buemi, Maria Rosa; Di Fiore, Anna; De Luca, Laura; Angeli, Andrea; Mancuso, Francesca; Ferro, Stefania; Monti, Simona Maria; Buonanno, Martina; Russo, Emilio; De Sarro, Giovanbattista; De Simone, Giuseppina; Supuran, Claudiu T.; Gitto, Rosaria published an article.Safety of 4-(4-Chlorophenyl)piperidin-4-ol The title of the article was Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety. And the article contained the following:

Guided by the crystal structure of 4-(3,4-dihydroquinolin-1(2H)-ylcarbonyl)benzenesulfonamide in complex with hCA II (PDB code 4Z0Q), a novel series of cycloalkylamino-1-carbonylbenzenesulfonamides was designed and synthesized. Thus, we replaced the quinoline ring with an azepine/piperidine/piperazine nucleus and introduced further modifications on cycloalkylamine nucleus by means the installation of hydrophobic/hydrophilic functionalities able to establish addnl. contacts in the middle area of the enzyme cavity. Among the synthesized compounds, the derivatives 7a, 7b, 8b (I – III, resp.) exhibited a remarkable inhibition for hCA II and the brain-expressed hCA VII in sub-nanomolar range. The binding of these mols. to the target enzymes was characterized by means of a crystallog. anal., providing a clear snapshot of the most important interactions established by this class of inhibitors into the hCA II and hCA VII catalytic site. Notably, our results showed that the benzylpiperazine tail of compound 8b is oriented both in hCA II and in hCA VII toward a poorly explored region of the active site. These features should be further investigated for the design of new isoform selective CA inhibitors. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Safety of 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to cycloalkylaminocarbonylbenzenesulfonamide human carbonic anhydrase inhibitor structure, benzenesulfonamides, ca inhibitors, carbonic anhydrases, x-ray crystallography, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Sulfenic, Sulfinic, and Sulfonic Acids and Derivatives and other aspects.Safety of 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On July 18, 2018, Chen, Yiding; Murray, Philip R. D.; Davies, Alyn T.; Willis, Michael C. published an article.Recommanded Product: 39512-49-7 The title of the article was Direct Copper-Catalyzed Three-Component Synthesis of Sulfonamides. And the article contained the following:

Sulfonamides such as N-(phenylsulfonyl)morpholine were prepared in one step by coupling of aryl-, heteroaryl-, and alkenylboronic acids such as phenylboronic acid with cyclic and acyclic alkyl secondary amines such as morpholine and primary anilines and the bis(sulfur dioxide) complex of DABCO (DABSO) in the presence of Cu(OTf)2 and 4,4′-dimethoxy-2,2′-bipyridine in DMSO. The method was used on gram scale and was used to prepare sulfonamides from drugs and drug fragments. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Recommanded Product: 39512-49-7

The Article related to aryl heteroaryl alkenyl sulfonamide preparation, copper catalyst coupling boronic acid amine dabso, secondary cyclic acyclic amine aniline coupling boronic acid dabso, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Sulfenic, Sulfinic, and Sulfonic Acids and Derivatives and other aspects.Recommanded Product: 39512-49-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On August 26, 2021, Palmer, Wylie Solang; Wu, Jeffrey; Zipfel, Sheila; Ozboya, Kerem; Weiss, Dahlia published a patent.Quality Control of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid The title of the patent was Preparation of bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof. And the patent contained the following:

The present disclosure provides bifunctional compounds I [R1 = (un)substituted C1-10 alkyl, C3-10 cycloalkyl, or 3-12 membered heterocyclyl; L = L1L2L3L4L5, each L1-L5 being independently: (a) (un)substituted C3-12 cycloalkyl, (b) (un)substituted C6-12 aryl, (c) (un)substituted 3-12 membered heterocyclyl, etc.; LHM = a ligase harness moiety] or pharmaceutically acceptable salts as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4. E.g., a multi-step synthesis of II, starting from Me 4,6-dichloropyridine-3-carboxylate and tetrahydropyran-4-amine hydrochloride, was described. IRAK4 degradation of exemplified compounds I were measured in multiple runs using HTRF assay and HiBit assay (data given). Pharmaceutical composition comprising I was disclosed. The experimental process involved the reaction of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid(cas: 1216805-11-6).Quality Control of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid

The Article related to interleukin1 receptor associated kinase irak4 bifunctional degrader pyrrolopyridazinecarbonitrile preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Quality Control of 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindoline-5-carboxylic acid

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 30, 2021, Araujo, Erika; Sparks, Steven M.; Berlin, Michael; Zhang, Wei; Wang, Jing published a patent.Reference of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate The title of the patent was Indazole based compounds and associated methods of use. And the patent contained the following:

Bifunctional compounds (e.g., I), which find utility as modulators of leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacol. activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Reference of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

The Article related to indazole hetero bifunctional leucine rich repeat kinase inhibitor preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Reference of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On April 23, 2020, Blake, James F.; Boys, Mark Laurence; Chicarelli, Mark Joseph; Cook, Adam; Elsayed, Mohamed S. A.; Fell, Jay B.; Fischer, John P.; Hinklin, Ronald Jay; McNulty, Oren T.; Mejia, Macedonio J.; Rodriguez, Martha E.; Wong, Christina E. published a patent.HPLC of Formula: 362703-57-9 The title of the patent was Preparation of pyridopyrazines and related derivatives as SHP2 protein tyrosine phosphatase inhibitors. And the patent contained the following:

The invention is related to the preparation of compounds I [X1-3independently = CH, N; L1 = a bond, S, CH2, O, NH; R1 = (un)substituted Ph, heteroaryl, bicyclic hetero/aryl, bicyclic heterocyclyl; R2 = ; R48 = H, Me, 4-amino-4-methylpiperidin-1-yl, 1,7-diazaspiro[3.5]nonan-7-yl, 4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl, etc.] , their stereoisomers, tautomers and pharmaceutically acceptable salts, that inhibit SHP2 protein tyrosine phosphatase and are useful for treating hyperproliferative and neoplastic diseases. Methods of using compounds I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathol. conditions are disclosed. Thus, reaction of 6-chloropyrido[2,3-b]pyrazin-2-yl trifluoromethanesulfonate (preparation given) with tert-Bu (4-methylpiperidin-4-yl)carbamate, treatment of tert-Bu [1-(6-chloropyrido[2,3-b]pyrazin-2-yl)-4-methylpiperidin-4-yl]carbamate with 2-amino-3-chloropyridine-4-thiol (preparation given) and cleavage of the tert-butoxycarbonyl group gave II. Certain exemplary compounds were assayed for their SHP2 inhibition activity in an enzymic assay; II showed an iC50 of 33 nM. A cell- based assay was used to determine the effect of SHP2 inhibitors on downstream signaling by assaying ERK1/2 phosphorylation. The experimental process involved the reaction of tert-Butyl 4-amino-4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate(cas: 362703-57-9).HPLC of Formula: 362703-57-9

The Article related to pyridopyrazine preparation shp2 protein tyrosine phosphatase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.HPLC of Formula: 362703-57-9

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On April 30, 2020, Crew, Andrew P.; Hornberger, Keith R.; Wang, Jing; Crews, Craig M.; Jaime-Figueroa, Saul; Dong, Hanqing; Qian, Yimin; Zimmermann, Kurt published a patent.HPLC of Formula: 1251006-64-0 The title of the patent was Bifunctional heterocycles, their use in targeted degradation of rapidly accelerated fibrosarcoma polypeptides and their preparation. And the patent contained the following:

The present disclosure relates bifunctional compounds of formula ULM-L-PTM, their use in modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein) and treatment of diseases that result from aggregation or accumulation of the target protein. and their preparation Compounds of formula ULM-L-PTM, wherein ULM is a small mol. E3 ubiquitin ligase binding moiety; PTM is a small mol. comprising a RAF protein targeting moiety; L is a bond or chem. linking moiety connecting ULM and PTM; and pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, polymorph and prodrug thereof, are claimed. Compound I was prepared using a multistep procedure (procedure given). The present disclosure exhibits a broad range of pharmacol. activities associated with degradation/inhibition of target protein (data given). The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).HPLC of Formula: 1251006-64-0

The Article related to bifunctional heterocycle preparation raf modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.HPLC of Formula: 1251006-64-0

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 8, 2017, Himmelsbach, Frank; Blum, Andreas; Peters, Stefan published a patent.HPLC of Formula: 1251006-64-0 The title of the patent was Preparation of 4-cyanobenzyl carbamimidoylcarbamate derivatives as AOC3 inhibitors. And the patent contained the following:

The invention relates to new benzonitrile derivatives I [R1 = H or halo; R2 = H or halo;R3 = H or halo (with the proviso that not more than one of R1-R3 is halo); A = II-IV, etc. (R4 = pyrrolidinyl, piperidinyl, piperazinyl; a CH2 group of the pyrrolidinyl, oxazolidinyl, piperidinyl or piperazinyl group of R4 is optionally replaced with a C(O) group)] or a pharmaceutically acceptable salt thereof, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them. Over ninety compounds I were prepared E.g., a multi-step synthesis of compound V, starting from 4-bromo-2,5-difluoro-benzonitrile and 4-(piperazinyl)benzonitrile, was described. Exemplified compounds I were tested in the AOC3 assay (IC50 values given). The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).HPLC of Formula: 1251006-64-0

The Article related to cyanobenzyl carbamimidoylcarbamate aoc3 inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.HPLC of Formula: 1251006-64-0

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On October 22, 2013, Miyamoto, Yukiko; Kalisiak, Jaroslaw; Korthals, Keith; Lauwaet, Tineke; Cheung, Dae Young; Lozano, Ricardo; Cobo, Eduardo R.; Upcroft, Peter; Upcroft, Jacqueline A.; Berg, Douglas E.; Gillin, Frances D.; Fokin, Valery V.; Sharpless, K. Barry; Eckmann, Lars published an article.Application In Synthesis of 4-(4-Chlorophenyl)piperidin-4-ol The title of the article was Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity. And the article contained the following:

Metronidazole and other 5-nitroimidazoles (5-NI) are among the most effective antimicrobials available against many important anaerobic pathogens, but evolving resistance is threatening their long-term clin. utility. The common 5-NIs were developed decades ago, yet little 5-NI drug development has since taken place, leaving the true potential of this important drug class unexplored. Here we report on a unique approach to the modular synthesis of diversified 5-NIs for broad exploration of their antimicrobial potential. Many of the more than 650 synthesized compounds, carrying structurally diverse functional groups, have vastly improved activity against a range of microbes, including the pathogenic protozoa Giardia lamblia and Trichomonas vaginalis, and the bacterial pathogens Helicobacter pylori, Clostridium difficile, and Bacteroides fragilis. Furthermore, they can overcome different forms of drug resistance, and are active and nontoxic in animal infection models. These findings provide impetus to the development of structurally diverse, next-generation 5-NI drugs as agents in the antimicrobial armamentarium, thus ensuring their future viability as primary therapeutic agents against many clin. important infections. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Application In Synthesis of 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to nitroimidazole library preparation azide alkyne cycloaddition antimicrobial sar, antibiotics, infectious diseases, medicinal chemistry, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Application In Synthesis of 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On July 31, 1995, Nemeryuk, M. P.; Sedov, A. L.; Safonova, T. S.; Shvarts, G. Ya.; Faiermark, I. F.; Mashkovskii, M. D. published an article.COA of Formula: C9H13ClN4 The title of the article was Synthesis and pharmacological properties of 4(5)-substituted 5(4)-amidino-1,2,3-triazoles. And the article contained the following:

Title compounds I [R1 = R2 = Me; R1R2 = (CH2)5, (CH2)2O(CH2)2; R3 = Cl, MeO, PhCH2S, 3,4-Cl2C6H3CH2S] were prepared by diazotization of 4-(dialkylamino)-5-aminopyrimidines II in aqueous HCl. Triazole I [R1R2 = (CH2)2O(CH2)2; R3 = Cl] showed antihypertensive effect in rats at dose 10 mg/kg. It also showed low toxicity with LD50 > 1000 mg/kg. The experimental process involved the reaction of 4-Chloro-6-(piperidin-1-yl)pyrimidin-5-amine(cas: 84762-70-9).COA of Formula: C9H13ClN4

The Article related to amidinotriazole antihypertensive preparation, diazotization dialkylamino aminopyrimidine, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.COA of Formula: C9H13ClN4

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 14, 2017, Mainolfi, Nello; Moyer, Mikel P. published a patent.Electric Literature of 362703-57-9 The title of the patent was Indole-2-carboxamides as 3-phosphoglycerate dehydrogenase inhibitors and their preparation. And the patent contained the following:

The invention provides compoundsof formula I, compositions thereof, and methods of using the same. Compounds of formula I wherein R1 and R6 are independently H, C1-4 alkyl; R2 and R3 are independently halo, CN, (un)substituted C1-6 aliphatic, etc.; R4 is H, halo, CN, etc.; R8 os H, CO2H and derivs and (un)substituted C1-6 aliphatic group; R9 is H, halo and (un)substituted C1-4 alkyl; A is (un)saturated 3- to 8-membered carbocyclyl, (un)substituted 7- to 12-membered bicyclic carbocyclyl, (un)saturated 4- to 8-membered heterocyclyl, etc.; L1 is a bond and (un)branched C1-6 bivalent hydrocarbon chain wherein 1 to 5 methylene units may be replaced with O, CO, CO2, etc.; n is 0, 1, 2, 3, 4 and 5; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their PHGDH inhibitory activity (data given). The experimental process involved the reaction of tert-Butyl 4-amino-4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate(cas: 362703-57-9).Electric Literature of 362703-57-9

The Article related to indole carboxamide 3phosphoglycerate dehydrogenase inhibitor, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Electric Literature of 362703-57-9

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem